Blog

Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India

Jun 1 • 2 min read

Clearmind Medicine Inc. (CSE: CMND | OTC Pink: CMNDF | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, has been granted patent approval from the Office of the Controller-General of Patents, Designs and Trademarks in India. The patent refers to the company’s proprietary…

Hadas Alterman & Adriana Kertzer are Humanizing the Legal Process for Psychedelics – Podcast Episode #6

Jun 1 • 1 min read

On the sixth episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Hadas Alterman and Adriana Kertzer of the Plant Medicine Law Group. During the conversation, they uncover the importance of the work they’re doing for the industry and pave the legal path for the mass adoption of psychedelics. New episodes of…

Mydecine Announces Closing of Overnight Marketed Public Offering of Units

May 30 • 3 min read

Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: 0NFA) is pleased to announce that it has closed its previously announced best efforts overnight marketed offering of units through a syndicate of agents led by Stifel Nicolaus Canada Inc. and Roth Canada, Inc. Under the Offering, the Company issued 2,447,130 Units at a…

Small Pharma Shares Business Update Ahead of Annual Financial Results

May 30 • 8 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, provides a business update ahead of its annual financial results for the fiscal year ended February 28, 2022. All references to “$” in this press release refer to Canadian dollars unless otherwise indicated. Strengthening the…

Anthony Tennyson, CEO of Awakn Life Sciences Sits in the Investor Hotseat: Stream #1

May 30 • 46 min read

Psychedelic Invest’s first Investor Hotseat livestream was broadcasted live on Thursday, May 26th. Host, Dustin Robinson, of Iter Investments, was joined by Anthony Tennyson of Awakn Life Sciences. As the CEO of Awakn, Anthony was asked the questions every investor wants to know but never gets the chance to ask. This format of hard-hitting questions…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560